KRAS and lung carcinoma: Overall, lung cancers with KRAS mutations are characterized by a marked disease heterogeneity: KRAS mutational isoforms differ in their biochemical properties to hydrolyze GTP and to activate downstream signaling pathways, which determines differences in their biological behavior and therapeutic vulnerabilities [31,32,33].